Myeloid ecotropic viral integration site 1 inhibits cell proliferation, invasion or migration in human gastric cancer
- PMID: 29163810
- PMCID: PMC5685731
- DOI: 10.18632/oncotarget.21376
Myeloid ecotropic viral integration site 1 inhibits cell proliferation, invasion or migration in human gastric cancer
Retraction in
-
Retraction: Myeloid ecotropic viral integration site 1 inhibits cell proliferation, invasion or migration in human gastric cancer.Oncotarget. 2024 Sep 17;15:634. doi: 10.18632/oncotarget.28649. Oncotarget. 2024. PMID: 39288283 Free PMC article. No abstract available.
Abstract
Myeloid ecotropic viral integration site 1 (MEIS1) has been identified to be a potential tumor suppressor in some cancers. However, the mechanisms underlying MEIS1-induced cancer development and progression were not clear. Here, we investigated the expression and role of MEIS1 in gastric cancer. In vivo, we analyzed tumor growth using nude mice model. In the present study, MEIS1 expression was obviously decreased in GC cell lines compared with that in normal gastric cell lines (all p<0.001). MEIS1 overexpression inhibited cell proliferation and G1/S transition accompanied by decreased Cyclin D1 and Cyclin A expression. Furthermore, MEIS1 overexpression decreased the expression of Survivin, and induced cell apoptosis (p<0.001). Transwell migration assay revealed that MEIS1 affects cell invasion and migration, and inhibited epithelial-mesenchymal transition (EMT). Finally, MEIS1 inhibits MKN28 cell growth in nude mice model. In conclusion, our study suggested that MEIS1 plays an important role in regulating cell survival, proliferation, anchorage-independent growth, cell cycle, apoptosis and metastasis. Thus, MEIS1 might be recommended as an effective target for GC patients.
Keywords: MEIS1; gastric cancer; invasion; migration; proliferation.
Conflict of interest statement
CONFLICTS OF INTEREST The authors declare that they have no competing interests.
Figures
References
-
- Sugano K. Screening of gastric cancer in Asia. Best Pract Res Clin Gastroenterol. 2015;29:895–905. - PubMed
-
- Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, et al. MAGIC Trial Participants Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. - PubMed
-
- Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20. - PubMed
-
- Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, et al. CLASSIC trial investigators Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21. - PubMed
-
- Inaoka K, Kanda M, Uda H, Tanaka Y, Tanaka C, Kobayashi D, Takami H, Iwata N, Hayashi M, Niwa Y, Yamada S, Fujii T, Sugimoto H, et al. Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer. World J Gastroenterol. 2017;23:2519–2526. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
